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OBJECTIVES This meta-analysis compared amiodarone with placebo and class Ic drugs for the cardiover-
sion of recent-onset atrial fibrillation (AF), defined as lasting less than seven days.
BACKGROUND Despite the lack of trials that support its efficacy convincingly, amiodarone is widely used for
conversion of recent-onset AF.
METHODS We searched Medline and EMBASE databases, as well as the Cochrane Controlled Trials
Register for randomized trials on recent-onset AF comparing amiodarone to placebo or class
Ic drugs. Data were combined according to a fixed effect model. The primary end point was
the rate of conversion at 24 h. To study time-dependency of the drugs, efficacy at 1 to 2 h,
3 to 5 h, 6 to 8 h, and at 24 h was analyzed.
RESULTS We found six studies randomizing amiodarone versus placebo (595 patients) and seven studies
versus class Ic drugs (579 patients). There was no significant difference between amiodarone
and placebo at 1 to 2 h, but significant efficacy was found after 6 to 8 h (relative risk [RR]
1.23, p  0.022) and at 24 h (RR 1.44, p  0.001). Efficacy with amiodarone was inferior
to class Ic drugs for up to 8 h (RR 0.67, p  0.001) but no difference was seen at 24 h (RR
0.95, p  0.50). There were no major adverse effects.
CONCLUSIONS Amiodarone is superior to placebo for cardioversion of AF, and even though the onset of
conversion is delayed, its efficacy is similar at 24 h compared with class Ic drugs. These results
favor amiodarone as a reasonable alternative for patients with recent AF in whom class Ic and
other, more rapidly acting antiarrhythmic drugs cannot be used. (J Am Coll Cardiol 2003;
41:255–62) © 2003 by the American College of Cardiology Foundation
Termination of atrial fibrillation (AF) of recent onset,
defined as onset within one week (1), is a major issue in
daily clinical practice. The aim of prompt cardioversion is to
improve functional status, to reduce atrial remodeling which
may favor maintenance of arrhythmia, to reduce thrombo-
embolic complications, and to reduce duration of hospital-
ization and hence cost.
Cardioversion may be achieved by either pharmacologic
or electrical means. The success rate of electrical cardiover-
sion varies between 70% and 90% (1). Immediate electrical
cardioversion is indicated in patients with AF and a rapid
ventricular response who have evidence of acute myocardial
ischemia or symptomatic hypotension, angina, or heart
failure that do not respond promptly to pharmacologic
measures (1). Pharmacologic cardioversion may be other-
wise attempted, thus avoiding the inconvenience of general
anesthesia. For this purpose, class I and class III antiar-
rhythmic drugs have been studied. Class Ic drugs such as
propafenone (2–5) and flecainide (6,7) have been shown to
be efficacious. Among the class III agents, amiodarone was
the first to have been used. The reported efficacy in
converting AF is heterogeneous (8–13), and it has multiple
extracardiac side effects. Its relatively good tolerance in the
setting of heart failure and ischemic heart disease (14)
contributes to the popularity of this drug. Although amio-
darone is widely used to control AF, it is not approved in
North America for any supraventricular arrhythmia. Our
aim was to clarify by meta-analysis the role of amiodarone in
the cardioversion of recent-onset AF. This drug was com-
pared with placebo and with class Ic agents in randomized
trials. The main outcome measure was restoration of sinus
rhythm at 24 h.
METHODS
Search. We searched Medline and EMBASE databases
(from 1967, with the last electronic search on October 18,
2001), as well as the Cochrane Controlled Trials Register
for publications of randomized trials on cardioversion of AF
by amiodarone compared with placebo or class Ic antiar-
rhythmic drugs. Language of publication did not influence
article selection. References from these trials and from
related review articles or editorials were checked for addi-
tional studies. Abstracts from the annual scientific meetings
of the American Heart Association, the American College
of Cardiology, and the European Society of Cardiology
were overviewed from 1990 to 2001. Manufacturers were
contacted. Authors of papers were contacted when specific
data were unreported or ambiguous. Particular attention was
paid to identify duplicate reports.
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Inclusion and exclusion criteria. For inclusion, studies
had to be prospective, randomized controlled trials of
amiodarone versus placebo or versus a class Ic drug admin-
istered for cardioversion of recent-onset (1 week) AF.
Both blinded and open-label trials were included.
Trials in the setting of atrial flutter or postoperative AF
were excluded, as were those with active control groups
(using, for example, digoxin or verapamil as a control drug).
However, trials that used drugs such as digoxin for rate
control only in both treatment arms were included.
End points. The primary end point was the rate of cardio-
version within the first 24 h. The secondary end points were
rates of cardioversion at 1 to 2 h, 3 to 5 h, and 6 to 8 h,
mortality, proarrhythmia, and other adverse effects such as
bradycardia, hypotension, and heart failure.
Data extraction. Trials selected for review were screened
for information about patient characteristics, details of
administration, treatment crossover, efficacy in converting
to sinus rhythm, and adverse drug reactions. All data were
extracted by one author (A.D.-D.) and checked by at least
one other author independently. Authors agreed on ex-
tracted data by discussion.
Statistical analysis. Statistical analysis was done using the
EasyMA program developed by one of the authors (M.C.).
Analysis was made on an intention-to-treat basis. Relative
risks (RR) and 95% confidence intervals (CI) were calcu-
lated. Individual RR were combined according to a fixed
effect model, after having assessed for absence of heteroge-
neity by the Cochran Q test. In case of significant hetero-
geneity, a random effect model using Der Simonian and
Laird method was used to combine the results. Methods
based on odds ratio (Mantel-Haenszel and Peto methods)
were also used, yielding similar results. Significance for
association was inferred at the p  0.05 level.
RESULTS
Trial selection. The different search strategies yielded 79
potentially relevant articles, 69 of which were subsequently
excluded for various reasons. Twenty-eight studies had no
control group and 32 compared amiodarone with a drug
other than a Ic class or placebo. Of the remaining studies
comparing amiodarone versus placebo or class Ic drugs,
three were in the setting of postoperative AF, one was not
randomized, and two studied AF lasting 7 days. One
study randomized patients according to their date of birth
and was not considered (15). Two studies (9,16) contained
data from previously published reports (7,12). We consid-
ered only one original article (12) and one with a markedly
larger cohort (9).
A total of 10 studies were thus included (8–13,17–20).
Three studies were overlapping, that is, they compared
amiodarone with class Ic drugs as well as with placebo
(8,9,12). Six studies compared amiodarone with placebo
(8–13) and included 595 patients (group 1). Seven studies
compared amiodarone with a class Ic drug (8,9,11,12,17–
20) and included 807 patients, of whom 579 were analyzed
(group 2). The 228 patients excluded were from two studies
(9,18) comparing several protocols for the administration of
Ic drugs. Of these protocols, only intravenous propafenone
was analyzed to prevent double-counting of the amiodarone
patients and for more homogeneity. A study of patients with
AF of less than two weeks duration was nevertheless
included, as the mean duration of arrhythmia was only 24 h
(17). Another study (8) included a minority of patients with
postoperative AF and was included (results in this subgroup
were comparable to those of the other patients). No drop-
outs were mentioned in any of the studies.
Patient characteristics. In each study, patients were
matched as to age, gender, and duration of AF (Tables 1
and 2). Exclusion criteria were similar across the different
studies and usually concerned severe heart failure, recent
myocardial infarction, unstable angina, use of other antiar-
rhythmic drugs, severe conduction disturbances, thyroid
dysfunction, hyperkalemia, and severe renal or hepatic
insufficiency.
Use of beta-blockers and calcium channel antagonists was
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence intervals
RR  relative risk
Table 1. Characteristics of the Amiodarone Versus Placebo Studies
Study
No. of Patients
(Amio/P)
Mean Age
(yrs)
Gender
(% Male)
AF
Duration
Lone AF
(Amio/P) Blinding
Follow-Up
(h) Amiodarone
Boriani et al. (9) 51/121 58 55 7 days 20/54 Single 8 iv, 5 mg/kg bolus followed by
1.8 g/24 h
Cotter et al. (10) 50/50 66 43 48 h 22/22 Single 24 iv, 125 mg/h (total 3 g)
Donovan et al. (8) 32/32 66 NA 72 h NA Double 8 iv, 7 mg/kg
Galve et al. (11) 50/50 60 55 7 days 28/20 Single 24 iv, 5 mg/kg over 30 min followed
by 1.2 g over 24 h
Kochiadakis et al. (12) 48/49 64 55 48 h 29/28 NA 24 iv, 300 mg over 1 h followed by
20 mg/kg/24 h and 1.8 g/day po
Peuhkurinen et al. (13) 31/31 59 73 48 h NA Double 24 po, 30 mg/kg
AF  atrial fibrillation; Amio  amiodarone; iv  intravenous; Lone AF  atrial fibrillation without significant structural heart disease; NA  not available; P  placebo; po
 orally.
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Table 2. Characteristics of the Amiodarone Versus Class Ic Drugs Studies
Study
No. of Patients
(Amio/Ic)
Mean Age
(yrs)
Gender
(% male)
AF
Duration
Lone AF
(Amio/Ic) Blinding
Follow-up
(h) Amiodarone Ic Drug
Propafenone
Boriani et al. (9) 51/57 58 56 7 days 20/22 Single 8 iv, 5 mg/kg bolus followed by
1.8 g/24 h
iv, 2 mg/kg bolus followed by
0.0078 mg/kg/min
51/119 58 57 7 days 20/50 Single 8 iv, 5 mg/kg bolus followed by
1.8 g/24 h
po, 600 mg in a single dose
Blanc et al. (17) 43/43 62 66 2 weeks 14/14 Single 48 po, 30 mg/kg in a single dose po, 600 mg in a single dose
Kochiadakis et al. (12) 48/46 63 55 48 h 21/21 NA 24 iv, 300 mg over 1 h followed
by 20 mg/kg/24 h and 1.8
g/day orally
iv, 2 mg/kg over 15 min followed by
10 mg/kg over 24 h
Negrini et al. (19) 30/31 59 47 7 days 16/18 Single 24 iv, 5 mg/kg over 10 min
followed by 15 mg/kg over
24 h
iv, 2 mg/kg over 10 min followed by
10 mg/kg over 24 h
Martinez-Marcos et al. (18) 50/50 62 22 48 h NA Single 12 iv, 5 mg/kg followed by 50
mg/h
iv, 2 mg/kg in 20 min followed by
1 mg/kg in 20 min if needed after
8 h
Treglia et al. (20) 27/27 57 43 7 days 21/18 Single 48 iv, 5 mg/kg followed by 10
mg/kg/24 h
iv, 2 mg/kg followed by 5 mg/kg/
24 h
Flecainide
Boriani et al. (9) 51/69 59 56 7 days 20/27 Single 8 iv, 5 mg/kg over 30 s
followed by 10–15 mg/min
(total 5 mg/kg)
po, 300 mg in a single dose
Donovan et al. (8) 32/34 57 NA 72 h NA Double 8 iv, 7 mg/kg iv, 2 mg/kg
Martinez-Marcos et al. (18) 50/50 59 25 48 h NA Single 12 iv, 5 mg/kg followed by 50
mg/h
iv, 2 mg/kg in 20 min followed by
1 mg/kg if needed after 8 h
Abbreviations as in Table 1.
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permitted at randomization in two trials (8,10), as was
digoxin in one trial (19). Digoxin was used to slow heart rate
in three studies (10–12) when it exceeded 100/min. In one
study (13), verapamil was used in the placebo group to slow
the heart rate to below 100/min.
Strategies for anticoagulation (when reported) varied.
Examples are inclusion of patients with AF of 72 h
duration only if previous anticoagulation was given (9), and
routine transesophageal echocardiography in all patients
with AF  48 h without previous anticoagulation (17).
Treatment regimens. The different drug dosages and
schedules are detailed in Tables 1 and 2. Most trials
reported intravenous administration of a loading dose fol-
lowed by continuous infusion. Oral doses were most often
single. For intravenous amiodarone, dosages varied from a 7
mg/kg loading dose to a continuous 24-h infusion totaling
3 g. The dose of oral amiodarone was 30 mg/kg adminis-
tered during the first 24 h. Intravenous propafenone was
administered as a 2 mg/kg intravenous bolus followed by a
second dose of 1 mg/kg if needed, or an infusion of 5 to 10
mg/kg/24 h. Oral propafenone was given as a single 600-mg
dose. For flecainide, a 2 mg/kg intravenous bolus or a
300-mg oral dose was administered.
Patient follow-up. Follow-up varied from 8 to 48 h
(Tables 1 and 2). None of the studies in the amiodarone
versus placebo group reported efficacy at 3 to 5 h. All
patients were monitored by telemetry and blood pressure
recordings.
Meta-analysis. RETURN OF SINUS RHYTHM. Amiodarone
showed greater efficacy compared with placebo (Table 3,
Fig. 1) at 6 to 8 h (RR 1.23, 95% CI 1.03 to 1.47, p 
0.022) and at 24 h (RR 1.44, 95% CI 1.24 to 1.66, p 
0.001). The drug showed no significant efficacy at 1 to 2 h
(RR 1.23, 95% CI 0.77 to 1.96, p 0.39). The incidence of
spontaneous return of sinus rhythm must be emphasized, as
it varied between 35% and 64% at 24 h (Table 3). Because
of heterogeneity of results at 24 h, most probably owing to
the study by Peuhkurinen et al. (13), we tested different
random effects models which all gave the same results.
Class Ic drugs were more effective than amiodarone
(Table 4, Fig. 2) at 1 to 2 h (RR 0.35, 95% CI 0.24 to 0.50,
p  0.001), at 3 to 5 h (RR 0.44, 95% CI 0.31 to 0.61, p 
0.001), and at 6 to 8 h (RR 0.57, 95% CI 0.57 to 0.80, p 
0.001). However, at 24 h both drugs were equally effective
(RR 0.95, 95% CI 0.83 to 1.09, p  0.50). Because of
heterogeneity of the results at 1 to 2 h, random effects
models were used and gave similar results. Robustness of
our results was tested by sensitivity analysis. In group 1, after
excluding the study by Peuhkurinen et al. (13), results were
similar, other than for the 6- to 8-h time-point, when the
difference between amiodarone and placebo was not signif-
icant (RR 1.14, 95% CI 0.99 to 1.41, p  0.073). In group
2, the results were homogenous. The influence of route of
administration was tested by excluding studies using oral
amiodarone (13,17), with no difference in results.
SIDE EFFECTS. There were no deaths in any trials. Nonsus-
tained ventricular tachycardia was reported in two patients
in the amiodarone group (11,17) and in one patient given
propafenone (17). A single episode of sustained ventricular
tachycardia was observed in a patient receiving placebo (8).
Because of the small number of events, analysis of the data
was impossible. Four episodes of 1:1 atrial flutter were
reported, three in patients receiving flecainide (9,18) and
one in a patient on placebo (9). Other side effects, such as
hypotension, bradycardia, and heart failure were inconsis-
tently defined and reported and were thus impossible to
analyze accurately. However, most of these adverse events
(such as transient hypotension) were without consequence.
DISCUSSION
The main findings of our meta-analysis is that amiodarone
facilitates conversion of recent-onset AF to sinus rhythm
(with a 44% superiority in efficacy compared with placebo),
but with a delay of 8 to 24 h until the onset of antiarrhyth-
mic activity. This efficacy is comparable to that of class Ic
agents at 24 h after drug administration, although Ic drugs
showed a more rapid onset of action, with some effect
already apparent at 1 to 2 h after administration.
The slower onset of cardioversion using amiodarone
compared with class Ic drugs may have several explanations.
First, the blood level of the active metabolite of amiodarone
(desethylamiodarone) is still low 1 h after intravenous
administration, whereas that of flecainide attains a thera-
peutic concentration at that time-point (8). Second, amio-
darone has a complex pharmacokinetic profile with a mul-
Table 3. Efficacy of Amiodarone Versus Placebo in Converting AF to Sinus Rhythm at Various Time-Points
Study
Amio No.
of Patients
Placebo No.
of Patients
Conversion to Sinus Rhythm No. of Patients (%)
1–2 h 6–8 h 24 h
Amio Placebo Amio Placebo Amio Placebo
Boriani et al. (9) 51 121 3 (6) 11 (9) 29 (57) 45 (37) — —
Cotter et al. (10) 50 50 3 (6) 1 (2) 31 (62) 29 (58) 46 (92) 32 (64)
Donovan et al. (8) 32 32 11 (34) 7 (22) 19 (59) 18 (56) — —
Galve et al. (11) 50 50 15 (30) 12 (24) 24 (48) 23 (46) 34 (68) 30 (60)
Kochiadakis et al. (12) 48 49 — — — — 40 (83) 27 (55)
Peuhkurinen et al. (13) 31 31 4 (13) 1 (3) 16 (52) 6 (20) 27 (87) 11 (35)
Total n (%) 262 333 36 (17) 32 (11) 119 (56) 121 (43) 147 (82) 100 (56)
AF  atrial fibrillation; Amio  amiodarone.
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ticompartmental distribution and a long half-life, requiring
more time for sufficient tissue impregnation (21). Third, the
acute effect of amiodarone on atrial action potential duration
is not well established (22), and the antiarrhythmic effect
related to a prolonged refractory period may be retarded.
Even if cardioversion may be delayed compared with class
Ic drugs, amiodarone has the advantage of promptly slowing
a rapid ventricular rate (8,10,11,17). This may be due to
predominant beta-adrenergic and calcium channel blockade
observed early after intravenous amiodarone injection, the
class III effect being least identifiable at this stage (21).
Flecainide, on the other hand, shows little slowing of
Figure 1. Amiodarone versus placebo showing no efficacy for return to sinus rhythm at 1 to 2 h (left) and efficacy at 24 h (right). Graphical representation
shows relative risk and 95% confidence interval.
Table 4. Efficacy of Amiodarone Versus Class Ic Drugs in Converting AF to Sinus Rhythm at Various Time-Points
Study
Amio No.
of Patients
Placebo No.
of Patients
Conversion to Sinus Rhythm No. of Patients (%)
1–2 h 3–5 h 6–8 h 24 h
Amio Ic Amio Ic Amio Ic Amio Ic
Propafenone
Boriani et al. (9) 51 57 3 (6) 22 (39) 13 (25) 33 (58) 29 (57) 46 (75) — —
119 10 (8) 53 (45) 90 (76)
Blanc et al. (17) 43 43 — — 7 (16) 16 (37) 11 (26) 19 (44) 20 (47) 24 (56)
Kochiadakis et al. (12) 48 46 — — — — — — 40 (83) 36 (78)
Negrini et al. (19) 30 31 6 (20) 18 (58) 10 (30) 20 (64) 12 (40) 22 (71) 24 (80) 27 (87)
Martinez-Marcos et al. (18) 50 50 7 (14) 30 (60) — — 21 (42) 34 (68) — —
Treglia et al. (20) 27 27 1 (4) 7 (26) 3 (15) 13 (65) 7 (26) 15 (55) 13 (48) 18 (67)
Flecainide
Boriani et al. (9) 51 69 3 (6) 9 (13) 13 (25) 39 (56) 29 (57) 52 (75) — —
Donovan et al. (8) 32 34 11 (34) 20 (59) — — 19 (59) 23 (68) — —
Martinez-Marcos et al. (18) 50 50 7 (14) 29 (58) — — 21 (42) 41 (82) — —
Total 281* 526 28 (15) 139 (32) 23 (22) 174 (50) 99 (42) 301 (63) 97 (66) 104 (71)
*The amiodarone groups of the studies by Boriani et al. and Martinez-Marcos et al. are counted once.
Abbreviations as in Table 3.
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atrioventricular nodal conduction. Furthermore, this com-
pound has been shown to increase defibrillation thresholds,
whereas amiodarone has been shown to enhance electrical
cardioversion (23).
An alternative to amiodarone and class Ic drugs is
ibutilide, which has the advantage of rapidly converting AF,
making this a potentially useful drug in the emergency room
setting. A placebo-controlled study including patients with
a mean arrhythmia duration of about two weeks showed a
31% conversion rate with this drug (24). However, there
was an 8.3% incidence of polymorphic ventricular tachycar-
dia, which sometimes required electrical cardioversion.
Dofetilide is another new class III antiarrhythmic agent that
is effective in cardioverting AF (25). In a randomized trial
comparing intravenous dofetilide with amiodarone and
placebo in patients with AF of up to two months duration
(26), dofetilide achieved a higher cardioversion rate than
amiodarone and placebo (35%, 4%, and 4% of patients
respectively). However, the follow-up period in that study
was only 3 h, which may have been insufficient to show
efficacy of amiodarone. Furthermore, 8% of the patients
receiving dofetilide had torsade de pointes. These new class
III agents are most useful for cardioverting atrial flutter,
with efficacy rates of over 50% (24–26).
The issue of dosage and route of administration is difficult
to assess, as protocols varied widely between studies. Intra-
venous amiodarone has greater bioavailability than the oral
form, which is only 30% to 70% (21). It seems, furthermore,
that intravenous and oral amiodarone do not have the same
electrophysiologic effects, possibly owing to cumulative
effects and/or active metabolites (27). After a brief high-
dose oral load of amiodarone, the most pronounced prolon-
gation of refractoriness is seen in the atrium (28). On the
other hand, a single intravenous bolus dose has little impact
on the atrial action potential duration and refractory period
(29,30). In our meta-analysis, only one study used a single
intravenous bolus dose of 7 mg/kg of amiodarone and did
not show any efficacy in terminating AF (8). All the other
studies employed a continuous infusion of the drug, usually
preceded by a loading dose, resulting in a higher cumulative
dose. Only two studies (13,17) used oral amiodarone with a
single loading dose of 30 mg/kg, which was shown to be
effective (13). Overall, it appears that there are no significant
differences when the drug is used intravenously or orally, as
long as a sufficient dose is administered. The total daily dose
that may be given safely may be higher with the oral
formulation because hypotension is usually not seen (21).
Gastrointestinal side effects may, however, be problematic.
No serious side effects were reported with amiodarone.
Class Ic drugs have the potential of inducing atrial flutter
with 1:1 atrioventricular conduction, but this occurred only
exceptionally (in three patients on flecainide). Thus, both
amiodarone and class Ic drugs seem to be safe in the
population studied. However, there is evidence that class I
drugs may increase mortality in a subset of patients who may
benefit most from cardioversion, i.e., those with severe
underlying myocardial dysfunction or ischemic heart disease
(31). Amiodarone should also be used with caution in these
patients, as profound hypotension may be induced by
intravenous (32) or high-dose oral loading (33). Adminis-
Figure 2. Amiodarone versus class Ic drugs showing a greater efficacy of class Ic drugs for return to sinus rhythm at 1 to 2 h (left) but no difference at 24 h
(right). Graphical representation shows relative risk and 95% confidence interval.
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tration of the drug in critically ill patients has been reported
to lead to severe bradycardia which may result in death (34).
The incidence of extracardiac side effects due to short-term
administration of amiodarone is not well defined. However,
most of the toxicity of the drug seems to be dose-dependant
and related to chronic treatment (35).
Limits of the meta-analysis. As with all meta-analyses,
particular attention must be paid to the quality of the studies
included. We included only prospective, randomized con-
trolled studies. The time-points of analysis of efficacy varied
between the studies, and it was necessary to define separate
periods, resulting in a certain degree of heterogeneity. It
might also seem difficult to compare studies with diverging
results due to differences in study populations, drug dosage,
and routes of administration. However, sensitivity analyses
were done and showed robustness of our results. It must be
emphasized that the results of the meta-analysis apply to the
patient population studied, which consisted mostly of
middle-aged patients without major underlying heart dis-
ease, and that about half of the population had lone AF.
Finally, we were unable to accurately assess the incidence of
side effects, as reporting was inconsistent across studies.
CONCLUSIONS
Our meta-analysis was aimed at defining the role of amio-
darone in the conversion of recent-onset AF. The data show
that this drug is effective compared with placebo and that
even though the onset of conversion is delayed, efficacy is
similar at 24 h compared with class Ic drugs. In clinical
practice, amiodarone is a reasonable alternative to class Ic
drugs and may be the drug of choice in the setting of
ventricular dysfunction and ischemic heart disease if rapid
cardioversion is not required. Most of the data are on
intravenous amiodarone, and more studies using oral ad-
ministration need to be done. Finally, the issues of optimal
dosage and of out-patient treatment initiation should be
assessed.
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